Andes is focused on the research and development of new treatments and diagnostics for cancer, based on the inactivation of novel non-coding mitochondrial RNA targets by means of anti-sense and/or RNAi technology. Results to date indicate the potential for a universal and safe treatment.
www.andesbio.com
www.andesbio.com
Employees: 11-50
Founded date: 2017